MiMedx Group Inc (NASDAQ:MDXG) had a loss and met Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 3.80%.
MiMedx Group Inc Earnings Cheat Sheet
Revenue: Rose 177.05% to $13.52 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: reported adjusted EPS loss of $0.01 per share. By that measure, the company missed the mean analyst estimate of $-0.01. It beat the average revenue estimate of $12.94 million.
Quoting Management: “Pete” Petit, Chairman and CEO, said, “Fundamentally, the researchers proved, among other things, that our allografts attract critically important regenerative stem cells to the wound site to help repair the wound. In effect, the research confirms that our proprietary PURION® processed allografts act as a “stem cell magnet.”
Key Stats (on next page)…
Revenue decreased 0% from $0 in the previous quarter. EPS decreased to $-0.01 in the quarter versus EPS of $-0.02 in the previous quarter.
Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.01 to a loss $0. For the current year, the average estimate is a loss of $0.01, which is the same with that ninety days ago.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)